BRIEF published on 04/07/2026 at 07:05, 24 days 13 hours ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 24 days 13 hours ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 1 month 11 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 1 month 11 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 3 months 20 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 4 months 30 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 7 months 5 days ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 7 months 5 days ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 1 year 9 months ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 1 year 9 months ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 05/01/2026 at 18:00, 2 hours 27 minutes ago Star Copper to Present at the Emerging Growth Conference on May 7, 2026
Published on 05/01/2026 at 15:35, 4 hours 52 minutes ago LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement
Published on 05/01/2026 at 14:00, 6 hours 27 minutes ago CCL Industries Closing of ALT Technologies Acquisition
Published on 05/01/2026 at 14:00, 6 hours 27 minutes ago Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions
Published on 05/01/2026 at 13:01, 7 hours 26 minutes ago BeMetals Announces Resumption of Trading on TSX Venture Exchange and Effective Date of Share Consolidation
Published on 05/01/2026 at 19:23, 1 hour 3 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 2 hours 41 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 3 hours 5 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 19:16, 1 day 1 hour ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 1 hour ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 2 hours ago Minutes of the Combined General Meeting held on April 30, 2026
